Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
60.16
+0.91 (1.54%)
Apr 25, 2025, 12:05 PM EDT - Market open
Halozyme Therapeutics Revenue
In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth. Halozyme Therapeutics had revenue of $298.01M in the quarter ending December 31, 2024, with 29.55% growth.
Revenue (ttm)
$1.02B
Revenue Growth
+22.44%
P/S Ratio
7.40
Revenue / Employee
n/a
Employees
n/a
Market Cap
7.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
| Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
| Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
| Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
| Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
HALO News
- 1 day ago - Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation - PRNewsWire
- 14 days ago - Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - PRNewsWire
- 16 days ago - European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - PRNewsWire
- 18 days ago - European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - PRNewsWire
- 25 days ago - Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications - PRNewsWire
- 5 weeks ago - Halozyme Joins the $1 Billion Club - FXEmpire
- 2 months ago - Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference - PRNewsWire
- 2 months ago - Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript - Seeking Alpha